HTL Biotechnology launches HTL8
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
It was in 1934 that German chemist Karl Meyer and his British student John Palmer first isolated Hyaluronic Acid from the human body.
This year marks the 90th anniversary of the discovery of this molecule, which is used today in a large number of leading therapeutic areas and whose chemical specificities still conceal many discoveries for years to come.
To mark the occasion, HTL Biotechnology is committed to celebrating this anniversary throughout 2024. On the agenda : events and presentations on Hyaluronic Acid will guide you into the world of this fascinating molecule.
For the more curious among you, stay tuned by subscribing to the hashtag #90YearsofHAwithHTL ! 2024 is set to be a year full of learning and discovery !
A new production unit dedicated to pharmaceutical-grade Polynucleotides (DNA) at our Javené site.
HTL Biotechnology hosted a scientific summit in Chengdu, China, dedicated to PDRN/PN, bringing together more than 130 experts and professionals to discuss the latest scientific advances, regulatory developments and emerging applications.
Driven by the collective commitment of our teams, this report confirms the maturity of an internationally recognized approach, which was recognized this year with the EcoVadis Platinum medal, placing HTL Biotechnology among the top 1% of the world’s most committed companies.